Literature DB >> 36001124

ITHscore: comprehensive quantification of intra-tumor heterogeneity in NSCLC by multi-scale radiomic features.

Jiaqi Li1, Zhenbin Qiu2,3, Chao Zhang2,3, Sijie Chen1, Mengmin Wang2,3, Qiuchen Meng1, Haiming Lu1, Lei Wei1, Hairong Lv1,4, Wenzhao Zhong5,6, Xuegong Zhang7,8.   

Abstract

OBJECTIVES: To quantify intra-tumor heterogeneity (ITH) in non-small cell lung cancer (NSCLC) from computed tomography (CT) images.
METHODS: We developed a quantitative ITH measurement-ITHscore-by integrating local radiomic features and global pixel distribution patterns. The associations of ITHscore with tumor phenotypes, genotypes, and patient's prognosis were examined on six patient cohorts (n = 1399) to validate its effectiveness in characterizing ITH.
RESULTS: For stage I NSCLC, ITHscore was consistent with tumor progression from stage IA1 to IA3 (p < 0.001) and captured key pathological change in terms of malignancy (p < 0.001). ITHscore distinguished the presence of lymphovascular invasion (p = 0.003) and pleural invasion (p = 0.001) in tumors. ITHscore also separated patient groups with different overall survival (p = 0.004) and disease-free survival conditions (p = 0.005). Radiogenomic analysis showed that the level of ITHscore in stage I and stage II NSCLC is correlated with heterogeneity-related pathways. In addition, ITHscore was proved to be a stable measurement and can be applied to ITH quantification in head-and-neck cancer (HNC).
CONCLUSIONS: ITH in NSCLC can be quantified from CT images by ITHscore, which is an indicator for tumor phenotypes and patient's prognosis. KEY POINTS: • ITHscore provides a radiomic quantification of intra-tumor heterogeneity in NSCLC. • ITHscore is an indicator for tumor phenotypes and patient's prognosis. • ITHscore has the potential to be generalized to other cancer types such as HNC.
© 2022. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Non-small cell lung cancer; Radiomics; Tomography, X-ray computed; Tumor heterogeneity

Year:  2022        PMID: 36001124     DOI: 10.1007/s00330-022-09055-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   7.034


  35 in total

1.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

Review 2.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.

Authors:  Nicholas McGranahan; Charles Swanton
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study.

Authors:  Brian O'Sullivan; Shao Hui Huang; Jie Su; Adam S Garden; Erich M Sturgis; Kristina Dahlstrom; Nancy Lee; Nadeem Riaz; Xin Pei; Shlomo A Koyfman; David Adelstein; Brian B Burkey; Jeppe Friborg; Claus A Kristensen; Anita B Gothelf; Frank Hoebers; Bernd Kremer; Ernst-Jan Speel; Daniel W Bowles; David Raben; Sana D Karam; Eugene Yu; Wei Xu
Journal:  Lancet Oncol       Date:  2016-02-27       Impact factor: 41.316

Review 4.  The biology and management of non-small cell lung cancer.

Authors:  Roy S Herbst; Daniel Morgensztern; Chris Boshoff
Journal:  Nature       Date:  2018-01-24       Impact factor: 49.962

Review 5.  Intra-tumour heterogeneity: a looking glass for cancer?

Authors:  Andriy Marusyk; Vanessa Almendro; Kornelia Polyak
Journal:  Nat Rev Cancer       Date:  2012-04-19       Impact factor: 60.716

Review 6.  Therapeutic insights from genomic studies of head and neck squamous cell carcinomas.

Authors:  Peter S Hammerman; D Neil Hayes; Jennifer R Grandis
Journal:  Cancer Discov       Date:  2015-02-02       Impact factor: 39.397

Review 7.  Tumour heterogeneity and resistance to cancer therapies.

Authors:  Ibiayi Dagogo-Jack; Alice T Shaw
Journal:  Nat Rev Clin Oncol       Date:  2017-11-08       Impact factor: 66.675

Review 8.  Non-small-cell lung cancers: a heterogeneous set of diseases.

Authors:  Zhao Chen; Christine M Fillmore; Peter S Hammerman; Carla F Kim; Kwok-Kin Wong
Journal:  Nat Rev Cancer       Date:  2014-08       Impact factor: 60.716

Review 9.  Heterogeneity in Lung Cancer.

Authors:  Vitor Manuel Leitão de Sousa; Lina Carvalho
Journal:  Pathobiology       Date:  2018-04-10       Impact factor: 4.342

Review 10.  Translational implications of tumor heterogeneity.

Authors:  Mariam Jamal-Hanjani; Sergio A Quezada; James Larkin; Charles Swanton
Journal:  Clin Cancer Res       Date:  2015-03-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.